{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T18:35:57Z","timestamp":1778956557021,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-025-05451-9","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:47:00Z","timestamp":1738313220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fact-finding and risk factor analysis of chemotherapy-induced nausea and vomiting in children with solid tumors: a prospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Miaomiao","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xisi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"10","key":"5451_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11912-019-0840-0","volume":"21","author":"F Sherani","year":"2019","unstructured":"Sherani F, Boston C, Mba N. Latest update on prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients[J]. Curr Oncol Rep. 2019;21(10):89.","journal-title":"Curr Oncol Rep"},{"issue":"21","key":"5451_CR2","first-page":"382","volume":"119","author":"F Jahn","year":"2022","unstructured":"Jahn F, Wormann B, Brandt J, et al. The prevention and treatment of nausea and vomiting during tumor therapy[J]. Dtsch Arztebl Int. 2022;119(21):382\u201392.","journal-title":"Dtsch Arztebl Int"},{"key":"5451_CR3","doi-asserted-by":"crossref","unstructured":"Patel P, Robinson PD, Wahib N et al. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis[J]. Supportive Care Cancer 2022, 30(11): 8855\u201369.","DOI":"10.1007\/s00520-022-07287-w"},{"key":"5451_CR4","doi-asserted-by":"crossref","unstructured":"Tageja N, Groninger H. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines[J]. Postgrad Med J 2016,92(1083): 34\u201340.","DOI":"10.1136\/postgradmedj-2014-132969"},{"key":"5451_CR5","unstructured":"Natale JJ. Overview of the prevention and management of CINV[J]. Am J Manag Care 2018,24(18 Suppl): S391\u20137."},{"issue":"5","key":"5451_CR6","doi-asserted-by":"publisher","first-page":"e27646","DOI":"10.1002\/pbc.27646","volume":"66","author":"CSE Paw","year":"2019","unstructured":"Paw CSE, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline[J]. Pediatr Blood Cancer. 2019;66(5):e27646.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"5451_CR7","doi-asserted-by":"publisher","first-page":"e30395","DOI":"10.1002\/pbc.30395","volume":"70","author":"P Patel","year":"2023","unstructured":"Patel P, Robinson PD, Phillips R, et al. Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: clinical practice guideline update[J]. Pediatr Blood Cancer. 2023;70(8):e30395.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"5451_CR8","doi-asserted-by":"publisher","first-page":"e27488","DOI":"10.1002\/pbc.27488","volume":"66","author":"K McKinnon","year":"2019","unstructured":"McKinnon K, Jupp J, Ghosh S, et al. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals[J]. Pediatr Blood Cancer. 2019;66(1):e27488.","journal-title":"Pediatr Blood Cancer"},{"key":"5451_CR9","doi-asserted-by":"crossref","unstructured":"Zhao Y, Yang Y, Gao F et al. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)[J].EClinicalMedicine,2022,55: 101771.","DOI":"10.1016\/j.eclinm.2022.101771"},{"issue":"4","key":"5451_CR10","doi-asserted-by":"publisher","first-page":"e27584","DOI":"10.1002\/pbc.27584","volume":"66","author":"LL Dupuis","year":"2019","unstructured":"Dupuis LL, Tamura RN, Kelly KM, et al. Risk factors for chemotherapy-induced nausea in pediatric patients receivinhighly emetogenic chemotherapy[J]. Pediatr Blood Cancer. 2019;66(4):e27584.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"5451_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1177\/10781552221122026","volume":"29","author":"A Eliasen","year":"2023","unstructured":"Eliasen A, Kornholt J, Mathiasen R, et al. Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy[J]. J Oncol Pharm Pract. 2023;29(6):1361\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"5451_CR12","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1177\/0300060518765324","volume":"46","author":"A Ruggiero","year":"2018","unstructured":"Ruggiero A, Rizzo D, Catalano M, et al. Acute chemotherapy-induced nausea and vomiting in children with cancer: still waiting for a common consensus on treatment[J]. J Int Med Res. 2018;46(6):2149\u201356.","journal-title":"J Int Med Res"},{"key":"5451_CR13","doi-asserted-by":"crossref","unstructured":"Ewig CL, Yung WY, Ng H et al. A scoping review of nausea, vomiting and retching measurement methods in children with cancer[J].Pediatr Neonatol,2022,63(4): 331\u201340.","DOI":"10.1016\/j.pedneo.2021.12.010"},{"key":"5451_CR14","doi-asserted-by":"crossref","unstructured":"Patel P, Lavoratore SR, Flank J et al. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study[J]. Support Care Cancer 2020,28(2): 933\u20138.","DOI":"10.1007\/s00520-019-04903-0"},{"issue":"22","key":"5451_CR15","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1200\/JCO.20.00134","volume":"38","author":"LL Dupuis","year":"2020","unstructured":"Dupuis LL, Tomlinson GA, Pong A, et al. Factors associated with chemotherapy-induced vomiting control in pediatric patients receiving moderately or highly emetogenic chemotherapy: a pooled analysis[J]. J Clin Oncol. 2020;38(22):2499\u2013509.","journal-title":"J Clin Oncol"},{"key":"5451_CR16","doi-asserted-by":"crossref","unstructured":"Patel P, Leeder JS, Piquette-Miller M et al. Aprepitant and fosaprepitant drug interactions: a systematic review[J]. Brit J Clin Pharmaco 2017,83(10): 2148\u201362.","DOI":"10.1111\/bcp.13322"},{"key":"5451_CR17","doi-asserted-by":"crossref","unstructured":"Barusic AK. The emerging role of olanzapine in paediatric CINV control: a review[J].Medicine,2022,101(50): e32116.","DOI":"10.1097\/MD.0000000000032116"},{"key":"5451_CR18","doi-asserted-by":"crossref","unstructured":"Patel P, Robinson PD, Cohen M et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline[J]. Pediatr Blood Cancer 2022,69(12): e30001.","DOI":"10.1002\/pbc.30001"},{"key":"5451_CR19","doi-asserted-by":"crossref","unstructured":"Navari RM. Management of chemotherapy-induced nausea and vomiting in pediatric patients[J].Pediatr Drugs,2017,19(3): 213\u201322.","DOI":"10.1007\/s40272-017-0228-2"},{"key":"5451_CR20","doi-asserted-by":"crossref","unstructured":"Kovacs G, Wachtel AE, Basharova EV et al. Palonosetron versus Ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study[J].Lancet Oncol,2016,17(3): 332\u201344.","DOI":"10.1016\/S1470-2045(15)00520-3"},{"key":"5451_CR21","doi-asserted-by":"crossref","unstructured":"Li Z, Li C, Li P et al. Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial[J]. Adv Clin Exp Med 2022,31(3): 223\u201330.","DOI":"10.17219\/acem\/142332"},{"issue":"9","key":"5451_CR22","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1007\/s00520-018-4158-5","volume":"26","author":"S Jain","year":"2018","unstructured":"Jain S, Kapoor G, Koneru S, et al. A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy[J]. Support Care Cancer. 2018;26(9):3091\u20137.","journal-title":"Support Care Cancer"},{"key":"5451_CR23","doi-asserted-by":"crossref","unstructured":"Clemons M. Guidelines versus individualized care for the management of CINV[J].Support Care Cancer,2018,26(Suppl 1): 11\u20137.","DOI":"10.1007\/s00520-018-4115-3"},{"key":"5451_CR24","doi-asserted-by":"crossref","unstructured":"Tsuji D, Suzuki K, Kawasaki Y et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial[J]. Support Care Cancer 2019,27(3): 1139\u201347.","DOI":"10.1007\/s00520-018-4403-y"},{"key":"5451_CR25","doi-asserted-by":"crossref","unstructured":"[47] Dranitsaris G, Molassiotis A, Clemons M et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting[J]. Ann Oncol 2017, 28(6): 1260\u20137.","DOI":"10.1093\/annonc\/mdx100"},{"key":"5451_CR26","doi-asserted-by":"crossref","unstructured":"Vanbockstael J, Coquan E, Gouerant S et al. How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study[J]. Support Care Cancer 2016,24(3): 1131\u20138.","DOI":"10.1007\/s00520-015-2882-7"},{"key":"5451_CR27","doi-asserted-by":"crossref","unstructured":"Kishimoto K, Kawasaki K, Saito A et al. Prevention of chemotherapy-induced vomiting in children receiving multiple-day cisplatin chemotherapy: a hospital-based, retrospective cohort study[J]. Pediatr Blood Cancer,2017, 64(9).","DOI":"10.1002\/pbc.26485"},{"key":"5451_CR28","doi-asserted-by":"crossref","unstructured":"Ono A, Kishimoto K, Hasegawa K, D, et al. Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia. Support Care Cancer. 2019;27(3):895\u20139.","DOI":"10.1007\/s00520-018-4377-9"},{"key":"5451_CR29","doi-asserted-by":"crossref","unstructured":"Eliasen A, Kornholt J, Mathiasen R et al. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study[J].Pharmacogenet Genom,2022,32(2): 72\u20138.","DOI":"10.1097\/FPC.0000000000000460"},{"key":"5451_CR30","doi-asserted-by":"crossref","unstructured":"Eliasen A, Abildtoft MK, Krogh NS et al. Smartphone App to self-monitor nausea during Pediatric Chemotherapy Treatment: user-centered design Process[J].Jmir Mhealth Uhealth,2020,8(7): e18564.","DOI":"10.2196\/18564"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05451-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:47:17Z","timestamp":1738313237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05451-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5451"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05451-9","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and the ethical standards of the institutional and\/or national research committee and was approved by the Research Ethics Board of Beijing Children\u2019s Hospital of Capital Medical University (2022-E-182-Y).The study was non-interventional, posed no additional risks, and verbal informed consent was obtained from the patients or guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}